전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved34 programs
ADCCurated CoreFDAAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
CGTCurated CoreFDAFerring PharmaceuticalsApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 10Status Approved
CGTStandard DatabasestaleZhongmou TherapeuticsPhase 2

high dose (ZM-02, ZM-02 (high dose))

Retinitis Pigmentosa (RP) · Retinitis Pigmentosa (RP)

#RetinitisPigmentosaRP#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 62Status Recruiting
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+3
Trials 61Status Active
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

High (injection of scAAV2-P1ND4v2 2.4 X10e10vg, injection of scAAV2-P1ND4v2 2.4 X10e10vg (High))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 61Status Active
CGTStandard DatabasestaleImmunityBio, Inc.Phase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#Popular#cell-gene-therapy+3
Trials 59Status Discontinued
CGTStandard DatabasestaleImmunityBio, Inc.Phase 2

IL-15 Superagonist (N-803, N-803 (IL-15 Superagonist))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 57Status Discontinued
ADCStandard DatabasestaleRochevedotin, rituximab, cycloph…Phase 2

Polatuzumab (Polatuzumab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 52Status Recruiting
CGTLimited DatastaleTrogenix ltdPhase 2

Valaciclovir (Valaciclovir)

Glioblastoma (GBM); High Grade Gliomas · Glioblastoma (GBM)

#GlioblastomaGBM#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 51Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Belatacept (Belatacept)

Highly Sensitized Prospective Kidney Transplant Recipients · Kidney Transplantation

#KidneyTransplantation#Antibody#Phase2#monoclonal-antibody#HighlySensitizedProspectiveKidne+2
Trials 48Status Active
ADCStandard DatabasestaleADC TherapeuticsPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+2
Trials 48Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
AntibodyLimited DatastaleBayerPhase 2

anetumab ravtansine (anetumab ravtansine)

Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#monoclonal-antibody#FallopianTubeEndometrioidAdenoca+2
Trials 14Status Discontinued
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTStandard DatabasestaleImmunityBio, Inc.Phase 2

PSA-based Oncolytic Virus (ETBX-071, ETBX-071 (PSA-based Oncolytic Virus))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Discontinued
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

Murine CART19 (Murine CART19)

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL; Infants With Very High Risk KMT2A B-ALL · Pediatric and Young Adult Patientswith H

#PediatricandYoungAdultPatientswi#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
AntibodyLimited DatastaleNovartisPhase 3

Experimental: Secukinumab high dose (Experimental: Secukinumab high dose)

Chronic Severe Plaque-type Psoriasis · Chronic Severe Plaque-type Psoriasis

#ChronicSeverePlaque-typePsoriasi#Antibody#Phase3#monoclonal-antibody#Novartis
Trials 2Status Active
CGTLimited DatastaleSeoul National University Hospi…Phase 2

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Very High Risk Acute Lymphoblastic Leukemia; CD19 CAR-T Therapy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleCG Oncology, Inc.Phase 2

oncolytic adenovirus expressing GMCSF (oncolytic adenovirus expressing GMCSF)

Bladder Cancer; High Grade · Bladder Cancer

#BladderCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued

1 / 2 pages

← PreviousNext →